[1]DYSON JK, MCPHERSON S, ANSTEE QM.Republished:non-alcoholic fatty liver disease:non-invasive investigation and risk stratification[J].Postgrad Med J, 2014, 90 (1063) :254-266.
|
[2]LEMOINE M, SERFATY L.Nonalcoholic fatty liver disease[J].Presse Med, 2011, 41 (2) :169-189.
|
[3]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J].Gastroenterology, 2012, 142 (7) :1592-1609.
|
[4] The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association.Guidelines for management of nonalcoholic fatty liver disease:an updated and revised edition[J].Chin J Hepatol, 2010, 18 (3) :163-166. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版) [J].中华肝脏病杂志, 2010, 18 (3) :163-166.
|
[5]FAN JG, FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol, 2009, 50 (1) :204-210.
|
[6]HAMAGUCHI M, KOJIMA T, TAKEDA N, et al.The metabolic syndrome as a predictor of nonalcoholic fatty liver disease[J].Ann Intern Med, 2005, 143 (10) :722-728.
|
[7]BYRNE CD.Dorothy Hodgkin Lecture 2012:non-alcoholic fatty liver disease, insulin resistance and ectopic fat:a new problem in diabetes management[J].Diabet Med, 2012, 29 (9) :1098-1107.
|
[8]PAIS R, CHARLOTTE F, FEDCHUK L, et al.A systematic review of follow-up biopsies reveals disease progression in patients with nonalcoholic fatty liver[J].J Hepatol, 2013, 59 (3) :550-556.
|
[9]DAM-LARSEN S, FRANZMANN M, ANDERSEN IB, et al.Long term prognosis of fatty liver:risk of chronic liver disease and death[J].Gut, 2004, 53 (5) :750-755.
|
[10]YAN P, HUANG ZQ, WANG LN, et al.Investigation of correlation between non-alcoholic fatty liver and risk factors of atherosclerosis[J].China Med Herald, 2013, 10 (6) :158-159, 162. (in Chinese) 鄢萍, 黄中清, 王丽宁, 等.非酒精性脂肪肝与动脉粥样硬化危险因素相关性调查[J].中国医药导报, 2013, 10 (6) :158-159, 162.
|
[11]de ALWIS NM, DAY CP.Non-alcoholic fatty liver disease:the mist gradually clears[J].J Hepatol, 2008, 48 (1) :104-112.
|
[12]FAN JG, SAIBARA T, CHITTURI S, et al.What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?[J].J Gastroenterol Hepatol, 2007, 22 (6) :794-800.
|
[13]HASHIMOTO E, YATSUJI S, KANEDA H, et al.The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease[J].Hepatol Res, 2005, 33 (2) :72-76.
|
[14]DAY CP.Non-alcoholic fatty liver disease:a massive problem[J].Clin Med, 2011, 11 (2) :176-178.
|
[15]MALAGUARNERA M, DI ROSA M, NICOLETTI F, et al.Molecular mechanisms involved in NAFLD progression[J].J Mol Med (Berl) , 2009, 87 (7) :679-695.
|
[16]WATANABE S, HORIE Y, KATAOKA E, et al.Non-alcoholic steatohepatitis and hepatocellular carcinoma:lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN) -deficient mice[J].J Gastroenterol Hepatol, 2007, 22 (1) :96-100.
|
[17]GUY CD, SUZUKI A, ZDANOWICZ M, et al.Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (6) :1711-1721.
|
[18]SYN WK, AGBOOLA KM, SWIDERSKA M, et al.NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease[J].Gut, 2012, 61 (9) :1323-1329.
|
[19]KOWDLEY KV, BELT P, WILSON LA, et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology, 2011, 55 (1) :77-85.
|
[20] WREE A, MCGEOUGH MD, PENA CA, et al.NLRP3 inflammasome activation is required for fibrosis development in NAFLD[J].J Mol Med (Berl) , 2014, 92 (10) :1069-1082.
|
[21]VUPPALANCHI R, CHALASANI N.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:selected practical issues in their evaluation and management[J].Hepatology, 2009, 49 (1) :306-317.
|
[22]HASHIMOTO E, TANIAI M, TOKUSHIGE K.Characteristics and diagnosis of NAFLD/NASH[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 4) :64-70.
|
[23]HASHIMOTO E, TOKUSHIGE K, LUDWIG J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:current concepts and remaining challenges[J].Hepatol Res, 2014.[Epub ahead of print]
|
[24]XUN YH, GUO JC, LOU GQ, et al.Nonalcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6 years overall mortality of Chinese patients with NAFLD[J].Clin Exp Pharmacol Physiol, 2014, 41 (9) :643-649.
|
[25]MEHTA SR, THOMAS EL, BELL JD, et al.Non-invasive means of measuring hepatic fat content[J].World J Gastroenterol, 2008, 14 (22) :3476-3483.
|
[26]YONEDA M, YONEDA M, MAWATARI H, et al.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) [J].Dig Liver Dis, 2008, 40 (5) :371-378.
|
[27]SASSO M, BEAUGRAND M, de LEDINGHEN V, et al.Controlled attenuation parameter (CAP) :a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis:preliminary study and validation in a cohort of patients with chronic liver disease from various causes[J].Ultrasound Med Biol, 2010, 36 (11) :1825-1835.
|
[28]RICCI PE, PITT A, KELLER PJ, et al.Effect of voxel position on single-voxel MR spectroscopy findings[J].AJNR Am J Neuroradiol, 2000, 21 (2) :367-374.
|
[29]WEBB M, YESHUA H, ZELBER-SAGI S, et al.Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis[J].AJR Am J Roentgenol, 2009, 192 (4) :909-914.
|